Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

What this episode covers

Visit https://www.peervoice.com/JQU860 to view the entire programme with slides. After completing “Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice”, participants will be able to: Recognise the role of HER2 as a target in cancer sites beyond breast and gastric; Explain the HER2 testing and scoring recommendations for gynaecological cancers; Summarise the clinical evidence for emerging HER2-directed therapies for HER2-positive gynaecological cancers; and Evaluate and manage the safety profile for emerging HER2-directed therapies for HER2-positive gynaecological cancers.

Distinct summary based on available episode metadata or transcript content.